Clermont-Ferrand, April 2, 2026 – CLERAD announces the acquisition of Ariane Medical Systems Ltd., a UK-based company specializing in the development and commercialization of contact XRAY Brachytherapy solution.
Founded in 2004, AMS developed and commercializes Papillon+, a contact XRAY Brachytherapy solution designed for the treatment of small, accessible tumors of the skin, breast, and rectum. This acquisition is fully aligned with CLERAD’s strategy to offer diagnostic and treatment support solutions that enable therapeutic de-escalation and minimally invasive surgery.
As part of this partnership, CLERAD and AMS will combine their commercial and technical strengths across the different continents in which they operate, in order to ensure optimal field presence and support their clients in the use of the Papillon+ system for contact therapy.
“This acquisition marks a major milestone in our international development and reinforces our commitment to deliver innovative medical solutions to improve patients’ quality of life” said Philippe Brette, President of CLERAD Group.
For more information:
Press contacts:
Philippe Brette – President/CEO
phbrette@clerad.fr
Amin AMIRI – Ariane Medical Systems Ltd – Chairman
About CLERAD
Since 2000, CLERAD has established itself as a key player in the detection of ionizing radiation, particularly in the medical field for the detection of radiolabeled tissues. Its products are leading tools for radioguided surgery, including sentinel lymph node biopsy (SLNB), SEED localization, and FDG detection—enabling the localization of metastatic and micrometastatic tumors.
Driven by the expertise of our teams, we continuously expand our portfolio of innovative technologies dedicated to oncology, providing a comprehensive range of devices for diagnosis, guidance, and treatment for each patient.
We are a leader in France and Europe, with an international presence. Our specialists support you daily across nuclear medicine, radiology, surgery, radiotherapy, and chemotherapy.
We design, develop, manufacture, and sell medical devices with a strong ambition: to enable more precise, safer, and less invasive procedures, in support of optimized patient care and therapeutic de-escalation.
